Graft-versus-host disease (GvHD) is a severe complication in the setting of allogeneic
hematopoietic stem cell transplantation (HSCT). Mesenchymal stromal cells (MSCs) have
been extensively used as second-line treatment for acute GvHD. Cord blood (CB) MSCs
display low immunogenicity which makes them suitable for an allogeneic use. Herein
we reported the infusion of CB-MSCs to treat three patients with severe resistant
aGvHD and two patients with overlap syndrome after HSCT.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
